{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:22:10Z","timestamp":1786969330662,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Lung transplant recipients are at high risk for severe cytomegalovirus (CMV) disease. Off\u2010label use of letermovir (LET) may avert myelotoxicity associated with valganciclovir (VGCV), but data in lung transplantation are limited. This study aims to evaluate the outcomes of LET prophylaxis among lung transplant recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, matched cohort study included lung transplant recipients who received LET for primary CMV prophylaxis following VGCV intolerance. Patients were matched 1:1 to historical VGCV controls based on age, serostatus group, and time from transplant. The primary outcome was CMV breakthrough within 1 year post\u2010LET initiation; secondary outcomes included hematologic changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 124 lung transplant recipients were included per group (32% CMV mismatch, D+R\u2010), with LET initiated a median of 9.6 months post\u2010transplantation. One CMV breakthrough event (0.8%) was observed in the LET group versus four (3.2%) in the VGCV group (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.370). The median (interquartile range) white blood cell (WBC) count was\u00a03.1 (2.1\u20135.6)\u00a0at LET initiation which increased to\u00a05.1 (3.9\u20137.2)\u00a0at the end of follow\u2010up (<jats:italic>p<\/jats:italic> &lt;.001). For VGCV controls, WBC was\u00a04.8 (3.4\u20137.2)\u00a0at baseline and\u00a05.4 (3.6\u20137.2)\u00a0at the end of follow\u2010up; this difference was not statistically significant (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.395). Additionally, 98.4% of LET patients experienced \u22651 leukopenia episode in the year prior to LET compared to 71.8% the year after initiation (<jats:italic>p<\/jats:italic> &lt;.001). Similar results were observed for neutropenia (48.4% and 17.7%, <jats:italic>p<\/jats:italic> &lt;.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LET prophylaxis was associated with a low rate of CMV reactivation and leukopenia recovery. LET may represent a reasonable prophylaxis option for lung transplant recipients unable to tolerate VGCV.\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid14279-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.14279","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T10:28:12Z","timestamp":1715682492000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3369-3792","authenticated-orcid":false,"given":"Sydni","family":"Martinez","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-3622","authenticated-orcid":false,"given":"Devika","family":"Sindu","sequence":"additional","affiliation":[{"name":"Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Nailor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5042-0236","authenticated-orcid":false,"given":"Lauren","family":"Cherrier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"},{"name":"Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-8776","authenticated-orcid":false,"given":"Sofya","family":"Tokman","sequence":"additional","affiliation":[{"name":"Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-2921","authenticated-orcid":false,"given":"Rajat","family":"Walia","sequence":"additional","affiliation":[{"name":"Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-0891","authenticated-orcid":false,"given":"Kellie J.","family":"Goodlet","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Midwestern University College of Pharmacy  Glendale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/514340"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz215"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2012.00723.x"},{"key":"e_1_2_10_7_1","volume-title":"Letermovir","year":"2019"},{"key":"e_1_2_10_8_1","first-page":"31","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high\u2010risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye AP","year":"2023","journal-title":"JAMA"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(07)09"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9100"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13166"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.12.005"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/transplantology2020013"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13570"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ea3955"},{"key":"e_1_2_10_16_1","first-page":"14","article-title":"Implementation and validation of the Roche Light Cycler 480 96\u2010well plate platform as a real\u2010time PCR assay for the quantitative detection of cytomegalovirus (CMV) in clinical specimens using the Luminex MultiCode ASRs system","volume":"8","author":"Li SC","year":"2020","journal-title":"Med Sci"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14267"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab752"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.05.09"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16450"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15135"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201805-0825OC"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.06.014"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2018.10.034"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.10.008"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.14279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:53:11Z","timestamp":1718711591000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.14279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/tid.14279"],"URL":"https:\/\/doi.org\/10.1111\/tid.14279","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"2024-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14279"}}